Skip to navigation

Trk Family, RET and DDR

Trk family RTKs are genetically altered in multiple cancers including NTRK1 gene rearrangements in lung adenocarcninoma, NTRK1 and NTRK2 mutations in large cell neuroendocrine lung carcinoma, and NTRK3 gene fusions in multiple cancers including colorectal cancer. Mutations involving the DDR RTK have been identified in lung squamous cell carcinoma.

Trials Targeting Trk, RET and DDR


Indications: Non-Small Cell Lung Cancer
 
Drug Candidate: MGCD516
 
Driver Mutations: Trk, RET, DDR

A Phase 1 study evaluating the effects of MGCD516 as a treatment for patient with non-small cell lung cancer whose tumors carry genetic alterations of Trk, RET and DDR. Mirati and/or participating trial sites will analyze the molecular profile of the tumors of eligible patients to determine if those genetic alterations are present before enrolling in the clinical trial.

Find an Active Trial